Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

884 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluation of response to neoadjuvant chemotherapy in osteosarcoma using dynamic contrast-enhanced MRI: development and external validation of a model.
Kalisvaart GM, Van Den Berghe T, Grootjans W, Lejoly M, Huysse WCJ, Bovée JVMG, Creytens D, Gelderblom H, Speetjens FM, Lapeire L, van de Sande MAJ, Sys G, de Geus-Oei LF, Verstraete KL, Bloem JL. Kalisvaart GM, et al. Among authors: gelderblom h. Skeletal Radiol. 2024 Feb;53(2):319-328. doi: 10.1007/s00256-023-04402-8. Epub 2023 Jul 18. Skeletal Radiol. 2024. PMID: 37464020 Free PMC article.
Efficacy of eye movement desensitization and reprocessing therapy for fear of cancer recurrence among cancer survivors: a randomized single-case experimental design.
Bruin J, van Rood YR, Peeters KCMJ, de Roos C, Tanious R, Portielje JEA, Gelderblom H, Hinnen SCH. Bruin J, et al. Among authors: gelderblom h. Eur J Psychotraumatol. 2023;14(2):2203427. doi: 10.1080/20008066.2023.2203427. Eur J Psychotraumatol. 2023. PMID: 37144665 Free PMC article. Clinical Trial.
Thromboembolic and bleeding complications during interruptions and after discontinuation of anticoagulant treatment in patients with atrial fibrillation and active cancer: A daily practice evaluation.
Chu G, Seelig J, Cannegieter SC, Gelderblom H, Hovens MMC, Huisman MV, van der Hulle T, Trines SA, Vlot AJ, Versteeg HH, Hemels M, Klok FA. Chu G, et al. Among authors: gelderblom h. Thromb Res. 2023 Oct;230:98-104. doi: 10.1016/j.thromres.2023.08.016. Epub 2023 Aug 30. Thromb Res. 2023. PMID: 37703801 Free article.
Individualized Dosing Patterns in the Treatment of Older Patients with Gastrointestinal Stromal Tumors: Results of a Registry-Based Observational National Cohort Study Including 871 Patients.
Bleckman RF, Broekman KE, Roets E, Mohammadi M, Desar IME, Gelderblom H, Mathijssen RHJ, Steeghs N, de Graeff P, Reyners AKL. Bleckman RF, et al. Among authors: gelderblom h. Drugs Aging. 2024 Feb;41(2):165-176. doi: 10.1007/s40266-023-01084-8. Epub 2023 Dec 20. Drugs Aging. 2024. PMID: 38123766
A phase 4, multicenter, global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor previously treated with pexidartinib.
Desai J, Wagner AJ, Carrasco Garcia I, Cesari M, Gordon M, Lin CC, Papai Z, Ryan CW, Tap WD, Trent JC, Gelderblom H, Grimison P, López Pousa A, Van Tine BA, Rubinacci M, Dai D, Rajper AW, Tecson K, Wooddell M, Stacchiotti S. Desai J, et al. Among authors: gelderblom h. Cancer. 2024 Nov 12. doi: 10.1002/cncr.35634. Online ahead of print. Cancer. 2024. PMID: 39533157
Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non-Small Cell Lung Cancer-Results from the Drug Rediscovery Protocol.
Verkerk K, van der Wel TJWT, Zeverijn LJ, Geurts BS, Spiekman IAC, de Wit GF, Roepman P, Jansen AML, van der Noort V, Smit EF, Hoeben A, Hendriks LEL, van den Heuvel MM, Piet B, Herder GJM, Hashemi SMS, Gelderblom H, Verheul HMW, Voest EE, de Langen AJ. Verkerk K, et al. Among authors: gelderblom h. Clin Cancer Res. 2024 Dec 2;30(23):5323-5332. doi: 10.1158/1078-0432.CCR-24-1925. Clin Cancer Res. 2024. PMID: 39352721 Clinical Trial.
884 results